Clinical Trial Update: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating fluorescein for lymphatic mapping and sentinel lymph node biopsy in patients with stage I-II malignant melanoma has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignant Melanoma

Drugs mentioned

• Fluorescein (fluorescein sodium)

Snippet

Sponsor: University of Utah | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-12-20